Clinical Trial Update: Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1 [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety and efficacy of rhIGF-I/rhIGFBP-3 in Myotonic Dystrophy Type 1 has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myotonic Dystrophy Type

Drugs mentioned

• rhIGF-I/rhIGFBP-3 (recombinant human insulin-like growth factor I / recombinant human insulin-like growth factor binding protein-3)

Snippet

Sponsor: Insmed Incorporated | Conditions: Myotonic Dystrophy Type 1 | Phase 2 | Status: COMPLETED | Results posted: 2022-01-06